Skip to main content

Table 3 Biochemical assessments

From: Increased glycated albumin and decreased esRAGE levels in serum are related to negative coronary artery remodeling in patients with type 2 diabetes: an Intravascular ultrasound study

 

NR group

(N = 81)

IR/PR group

(N = 62)

P value

Total cholesterol (mmol/L)

4.43 ± 1.00

4.06 ± 0.96

0.029

Triglycerides (mmol/L)

2.11 ± 1.06

2.26 ± 1.51

0.498

HDL-C (mmol/L)

1.10 ± 0.26

1.06 ± 0.23

0.331

LDL-C (mmol/L)

2.57 ± 0.92

2.23 ± 0.71

0.017

Apo-A (mmol/L)

1.14 ± 0.18

1.11 ± 0.18

0.330

Apo-B (mmol/L)

0.90 ± 0.22

0.90 ± 0.22

0.902

Lp (a)

0.19 ± 0.11

0.19 ± 0.20

0.873

Fast glucose (mmol/L)

7.67 ± 2.82

7.38 ± 2.02

0.489

BUN (mmol/L)

5.94 ± 1.52

6.04 ± 1.82

0.718

Creatinine (mg/L)

84.84 ± 18.74

87.96 ± 30.66

0.454

Glycated haemoglobin (%)

7.92 ± 1.61

7.73 ± 1.39

0.451

hsCRP (mg/L)

5.33 ± 5.35

5.67 ± 7.02

0.745

esRAGE (ng/mL)

0.17 ± 0.09

0.24 ± 0.20

0.003

GA (%)

23.15 ± 5.24

19.64 ± 5.33

< 0.001

  1. NR, negative remodeling; IR/PR, intermediate or positive remodeling; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; Apo-A, apolipoprotein-A; Apo-B, apolipoprotein-B; Lp (a), lipoprotein (a); BUN, blood urea nitrogen; hsCRP, high sensitive C-reactive protein; esRAGE, endogenous secretory receptors for advanced glycation endproducts; GA, glycated albumin